Zimmer Biomet Holdings, Inc. $ZBH Stock: South Dakota Investment Council Decreases Stake

South Dakota Investment Council lowered its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH – Free Report) by 5.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 214,843 shares of the medical equipment provider’s stock after selling 12,842 shares during the quarter. South Dakota Investment Council owned 0.11% of Zimmer Biomet worth $19,085,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Allworth Financial LP lifted its stake in Zimmer Biomet by 5.1% during the 3rd quarter. Allworth Financial LP now owns 2,321 shares of the medical equipment provider’s stock valued at $200,000 after acquiring an additional 112 shares in the last quarter. Money Concepts Capital Corp grew its stake in shares of Zimmer Biomet by 3.1% in the 3rd quarter. Money Concepts Capital Corp now owns 3,754 shares of the medical equipment provider’s stock worth $333,000 after acquiring an additional 114 shares in the last quarter. Valeo Financial Advisors LLC grew its stake in shares of Zimmer Biomet by 1.6% in the 2nd quarter. Valeo Financial Advisors LLC now owns 11,176 shares of the medical equipment provider’s stock worth $962,000 after acquiring an additional 175 shares in the last quarter. Glenview Trust Co raised its holdings in shares of Zimmer Biomet by 3.7% in the third quarter. Glenview Trust Co now owns 5,067 shares of the medical equipment provider’s stock valued at $450,000 after purchasing an additional 179 shares during the last quarter. Finally, Parallel Advisors LLC raised its holdings in shares of Zimmer Biomet by 32.1% in the first quarter. Parallel Advisors LLC now owns 798 shares of the medical equipment provider’s stock valued at $72,000 after purchasing an additional 194 shares during the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Stock Up 0.7%

Shares of NYSE:ZBH opened at $102.17 on Wednesday. The company has a market capitalization of $19.34 billion, a PE ratio of 11.96, a price-to-earnings-growth ratio of 2.38 and a beta of 0.50. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.46 and a quick ratio of 0.79. The business has a fifty day moving average price of $96.00 and a two-hundred day moving average price of $92.73. Zimmer Biomet Holdings, Inc. has a 1 year low of $79.12 and a 1 year high of $112.54.

Zimmer Biomet (NYSE:ZBH – Get Free Report) last announced its earnings results on Wednesday, November 4th. The medical equipment provider reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.88 by $0.02. The firm had revenue of $2.06 billion during the quarter, compared to analyst estimates of $2.04 billion. Zimmer Biomet had a return on equity of 13.02% and a net margin of 8.95%. The business’s revenue was up 3.1% compared to the same quarter last year. During the same period last year, the firm posted $1.90 EPS. Analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.56 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.24 per share. The ex-dividend date was Wednesday, September 30th. This represents a $0.96 annualized dividend and a yield of 0.9%. Zimmer Biomet’s dividend payout ratio is presently 24.30%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Royal Bank Of Canada raised their price target on shares of Zimmer Biomet from $110.00 to $125.00 and gave the company an “outperform” rating in a research report on Thursday, November 5th. Truist Financial set a $114.00 price objective on shares of Zimmer Biomet in a research report on Thursday, November 5th. BMO Capital Markets decreased their price objective on shares of Zimmer Biomet from $102.00 to $101.00 and set a “market perform” rating for the company in a research note on Monday. Sanford C. Bernstein increased their price objective on shares of Zimmer Biomet from $93.00 to $107.00 and gave the company a “market perform” rating in a research note on Thursday, November 5th. Finally, Zacks Research raised shares of Zimmer Biomet from a “strong sell” rating to a “hold” rating in a research report on Tuesday, August 25th. Eight equities research analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $114.32.

Get Our Latest Stock Report on Zimmer Biomet

Trending Headlines about Zimmer Biomet

These are some of the ZBH headlines that stood out recently:

  • Positive Sentiment: Wells Fargo upgraded ZBH from “equal weight” to “overweight” and raised its price target to $123 from $113, citing the opportunity associated with the Monogram orthopedic robot. The new target implies about 20% upside from the cited share price. Zimmer Biomet upgraded at Wells Fargo on Monogram orthopedic robot
  • Positive Sentiment: Stifel raised its price target to $140 from $125 and reiterated a “buy” rating, signaling substantial potential upside in its view. Zimmer Biomet price target raised to $140 at Stifel
  • Negative Sentiment: BMO Capital Markets trimmed its target to $101 from $102 and maintained a “market perform” rating, reflecting a more guarded view and limited upside at the cited share price.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, insider Chad F. Phipps sold 3,000 shares of Zimmer Biomet stock in a transaction dated Friday, September 4th. The shares were sold at an average price of $98.35, for a total value of $295,050.00. Following the sale, the insider owned 65,231 shares of the company’s stock, valued at approximately $6,415,468.85. The trade was a 4.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Kevin R. Thornal sold 5,691 shares of the business’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $92.95, for a total transaction of $528,978.45. The disclosure for this sale is available in the SEC filing. Company insiders own 1.28% of the company’s stock.

Zimmer Biomet Profile

(Free Report)

Zimmer Biomet Holdings, Inc. develops and manufactures medical devices and technologies used in musculoskeletal care. Its products support orthopedic procedures involving the hip, knee, shoulder, and extremities, as well as trauma care, sports medicine, and related surgical applications. The company also offers surgical technologies, including robotic and digital solutions designed to assist clinicians with planning and performing procedures. Its products and services are used by hospitals, surgeons, and other healthcare providers.

Further Reading

Institutional Ownership by Quarter for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.